Lates News

CMB International Securities report states that Sanofi has signed the largest single asset transaction in the Chinese biopharmaceutical industry with Pfizer, with a prepayment of 1.25 billion US dollars and a total scale of 6 billion US dollars. The report indicates that the company had previously alerted investors about the potential license transfer of PD-1xVEGF and TL1A, with the further maturity of immunological assets expected to drive another round of valuation upgrades. Based on the company's rich product line, the company aims to launch around 10 products from this year to 2027 and submit new drug applications, continuously expand indications, develop internal new product lines, and expand verified business efforts in hair loss, skin diseases, and autoimmune product combinations. In addition, the company's ample cash position and continuously strengthened internal R&D team support the transformation. The bank maintains a "buy" rating on Sanofi with a target price raised to 25 Hong Kong dollars.